Form 4: Charles River Labs Exec Reports Share Transfer

Shannon M. Parisotto, EVP of Discovery & Safety Assessment at Charles River Laboratories, reported a transfer of 1,529 common shares to a revocable trust.

Summary

• Shannon M. Parisotto, Executive Vice President of Discovery & Safety Assessment at Charles River Laboratories International, Inc. (CRL), reported a transaction on June 5, 2026.
• The transaction involved the transfer of 1,529 shares of common stock.
• This transfer was made to a revocable trust controlled by the reporting person, exempt under Rule 16a-13.
• Following the transaction, Parisotto directly owns 9,853 shares and indirectly owns 9,680 shares through the trust, and beneficially owns 28,510 shares through Karpathos Investments LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine trust transfer by an executive and not a sale of shares.

Positives

• The reporting person continues to hold a significant number of shares, indicating ongoing commitment.
• The transfer to a revocable trust is a common estate planning or asset management strategy and does not inherently represent a sale or divestment of beneficial ownership.

Negatives

• No direct sale or disposition of shares was reported, so no immediate negative financial impact is evident from this specific transaction.

Risks

• No specific risks were mentioned in this filing.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Management Comments

• The transfer reflects the exempt transfer pursuant to Rule 16a-13 of 1,529 shares held by the reporting person to a revocable trust controlled by the reporting person.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. This specific filing indicates a trust-related transfer by a senior executive at Charles River Laboratories, a major player in the contract research organization (CRO) and drug development services sector, rather than a sale of stock.

Related Party Transactions

• Transfer of 1,529 shares to a revocable trust controlled by the reporting person.

Stakeholder Impact

• Shareholders: No immediate impact as beneficial ownership remains with the reporting person via a trust.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• No specific next steps were mentioned in this filing.

Key Dates

Keywords

Form 4, SEC Filing, Charles River Laboratories, Shannon M. Parisotto, Insider Transaction, Share Transfer, Revocable Trust, Beneficial Ownership